News Personalised vaccine against acute myeloid leukaemia

A personalised cancer vaccine for acute myeloid leukaemia (AML) induces an immune response and protects against relapse, according to a new study. Jacalyn Rosenblatt (Beth Israel Deaconess Medical Center, Boston, MA, USA) and colleagues serially vaccinated 17 patients with AML who were in complete remission after undergoing chemotherapy. The median age of the patients was 63 years. After a median follow-up of 57 months, 12 patients remained in remission (71%; 90% CI 52 –89%).
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research

Related Links:

(Wyss Institute for Biologically Inspired Engineering at Harvard) Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years. Chemotherapy has been the standard treatment for over 40 years, and while it often causes the cancer to go into remission, nearly half of patients experience disease relapse. Scientists at the Wyss Institute and Harvard SEAS have developed an injectable, biomaterial-based vaccine that, when combined with standard chemotherapy, caused complete and lasting recovery from and immunity against AML in mice.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Discussion This case demonstrates successful cure of pre-B-ALL complicating XLA by alloSCT with restoration of B-cell development and functional antibody response. We are aware of only one previous case of pre-B-ALL in an XLA patient (21), which suggests that human BTK deficiency in itself does not predispose to pre-B-ALL. However, there are data to suggest that BTK may act as a tumor suppressor, and BTK deficiency may predispose to tumor development following a “second hit.” Mice with a genetic deficiency in Slp65, a gene encoding an adaptor protein that functions together with BTK, have a block in progenito...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion Several TISC-based immunotherapeutic approaches are under development in various stages of preclinical studies. As outlined in this review article, a careful and more exhaustive genetic and metabolic understanding of TISC-associated phenotypes is critical to develop novel TISC based immunotherapies. Various components within the tumor microenvironment such as tumor cells, infiltrating immune cells, and supporting stromal cells impact the TISC metabolism. This unique metabolic profile leads to upregulation of certain enzymes and proteins such as ALDH1, CEP55, IDO COA1 etc., which can be utilized for development ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results Beatris Mastelic-Gavillet, Klara Balint, Caroline Boudousquie, Philippe O. Gannon and Lana E. Kandalaft* Department of Oncology, Center for Experimental Therapeutics, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland With the advent of combined immunotherapies, personalized dendritic cell (DC)-based vaccination could integrate the current standard of care for the treatment of a large variety of tumors. Due to their proficiency at antigen presentation, DC are key coordinators of the innate...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionASPH is overexpressed in approximately 40% of patients with AML and serves as a promising therapeutic target. An ASPH nanoparticle vaccine is currently under clinical investigation and has shown promising results in solid tumors. We plan to expand clinical testing of targeting ASPH to AML. The ASPH positivity cutoff established via this work will serve as the eligibility criterion for the planned phase Ib/IIa of anti-ASPH vaccination in AML..DisclosuresLebowitz: Sensei Biotherapeutics: Employment. Malhotra: Sensei Biotherapeutics: Employment. Fuller: Sensei Biotherapeutics: Employment. Shahlaee: Sensei Biotherape...
Source: Blood - Category: Hematology Authors: Tags: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis Source Type: research
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults and has a five-year survival rate under 50%. Most patients will relapse even after complete remission is achieved through standard chemotherapy. Thus, one barrier in current AML therapy is how to target the minimal residual disease during remission. Recent developments in understanding cancer cell antigen presentation and immunosuppression have revealed the promise of cancer immunotherapy in activating immune responses to target residual disease. Each leukemia patient has a unique spectrum of cell surface antigens, which are mostly uncharacterized. If...
Source: Blood - Category: Hematology Authors: Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Source Type: research
Conclusions: Our data demonstrate that a significant number of children lose preexisting humoral immunity against MMR and hepatitis B after completion of chemotherapy.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Original Articles Source Type: research
In this study, we have shown that the lipid chaperones FABP4/FABP5 are critical intermediate factors in the deterioration of metabolic systems during aging. Consistent with their roles in chronic inflammation and insulin resistance in young prediabetic mice, we found that FABPs promote the deterioration of glucose homeostasis; metabolic tissue pathologies, particularly in white and brown adipose tissue and liver; and local and systemic inflammation associated with aging. A systematic approach, including lipidomics and pathway-focused transcript analysis, revealed that calorie restriction (CR) and Fabp4/5 deficiency result ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusions: All patients had multiple abnormalities at end of therapy, and all patients had some degree of persistent immune dysfunction at 6 months after completion of therapy. Clinical implications of these laboratory abnormalities are currently unknown; longer term evaluations are ongoing. We demonstrate that survivors of childhood cancer have lasting quantitative and functional immunologic defects and may remain at risk for infectious complications after completion of therapy.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Original Articles Source Type: research
The WT1 vaccine moves closer to becoming the first FDA-approved, second-line treatment for malignant pleural mesothelioma. Kicking off this summer, the phase III clinical trial is expected to build on the recent, impressive success of a phase II trial that helped the vaccine obtain the U.S. Food and Drug Administration’s orphan drug designation. “We don’t want to overpromise at this point, but this could be quite exciting,” Dr. Andres Gutierrez, chief medical officer for Sellas Life Sciences Group, the biopharmaceutical company developing the vaccine, told Asbestos.com. “We believe we ar...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Research & Clinical Trials Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Leukemia | Middle East Health | Study | Vaccines